Novogene Co., Ltd. (SHA:688315)

Market Cap	6.51B
Revenue (ttm)	2.14B
Net Income (ttm)	203.35M
Shares Out	405.06M
EPS (ttm)	0.49
PE Ratio	33.08
Forward PE	28.92
Dividend	0.05 (0.31%)
Ex-Dividend Date	Jun 10, 2025

Volume	5,530,111
Average Volume	6,452,490
Open	16.29
Previous Close	16.31
Day's Range	16.00 - 16.49
52-Week Range	9.03 - 21.22
Beta	0.81
RSI	58.45
Earnings Date	Aug 15, 2025

About Paramount Global

Novogene Co., Ltd., together with its subsidiaries, provides genomic services and solutions in Mainland China, Hong Kong, Macau, Taiwan, and internationally. The company offers genomic solutions comprising human, animal, plant, and microbial whole genome sequencing, as well as human and mouse whole exome sequencing, microbial de novo sequencing, animal and plant de novo sequencing, and 12S/18S/ITS amplicon and shotgun metagenomic sequencing; transcriptomics solutions, such as mRNA, long non-coding RNA, small RNA, circular RNA, whole transcripto...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 2,202
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688315

Financial Performance

In 2024, Novogene's revenue was 2.11 billion, an increase of 5.45% compared to the previous year's 2.00 billion. Earnings were 196.79 million, an increase of 10.52%.